MSD< pharma
AZ and MSD impress at ASCO with Lynparza combo data in prostate cancer
June 5, 2018Research and Development ASCO, AstraZeneca, Cancer, MSD< pharma, Merck, lynparza, prostate cancer
In another major ASCO reveal, AstraZeneca and partner MSD lifted the curtain at the event on new data for its …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
